Noscheng Kinhua Pan FGFR Inhibitor Phase 2 clinical completion of the first patient in-group.

From: The medical missionrecently, Nocheng Jianhua announced that it has completed the first case of patient admission in the second phase of clinical study on the treatment of urinary skin cancer in the pan-FGFR inhibitor ICP-192ICP-192 is an innovative drug with global independent intellectual property rights, and is a high-selective small molecule pan-FGFR inhibitor that can be used to treat a variety of solid tumors, and is currently conducting clinical phase 1/2 studies in China and the United StatesIt is worth mentioning that two pan-FGFR inhibitors have been approved for sale worldwide, and no similar products have been approved in Chinacandidate ICP-192 is an innovative class 1 of small molecule-targeted drugs based on structural optimization design for high-efficiency selective pan-FGFR inhibitorsFGFR is a family of fibroblast growth factor tyrosine kinase receptors, including four subtypes of FGFR1-4, which play a key role in regulating cell proliferation and cell survivalThe pan-FGFR inhibitors that selectively bind and inhibit FGFR can block The FGFR-related signaling pathway, thereby controlling tumor cell proliferation and deathIn April, the product was approved for clinical trials in the United Statesthe first clinical study of patient sentry in This ICP-192 is a phase 2, multi-center, single-arm, open clinical trial conducted in China to evaluate the effectiveness and safety of ICP-192 in patients with advanced urinary tract cancer with abnormal lyingopathic fFR gene abnormalityProfessor Guo Jun of Beijing Cancer Hospital,, said: "The skin cancer of urinary tract is a common malignancy of the urinary system, of which 20% to 30% of the patients are accompanied by FGFR gene abnormalities, there is currently a lack of effective treatment for this part of the patient in China, there are still a large number of unmet clinical needs." So I'm looking forward to clinical trials of this new treatment, which will lead to better treatment options for patients"
Norcheng Jianhua Co-Founder, Chairman and CEO DrCui Yusong said: "ICP-192 is a highly selective new drug developed by Nocheng Jianhua, clinical phase 2 first patient group is another milestone we have achieved this year, we will work with researchers to advance the clinical research process, and strive to provide patients with more and better treatment options." "
currently, ICP-192 is currently conducting a number of clinical trials in China, including a Phase 2 study on bladder urinary skin cancer and a Phase 1 study on advanced solid tumorsIn addition, in addition to single-drug treatments, Nosh Kinhua will collect additional data to evaluate the combination of ICP-192 and immunocheckpoint inhibitors as a potential treatment option for patients with FGFR mutationsfact, The FGFR gene abnormality is not only present in the skin cancer of the urinary tract The FGFR gene variant caused by gene fusion, overexpression or mutation has been identified as an important potential therapeutic target for a variety of cancers, including hepatic bile duct cell carcinoma, urinary path skin (bladder) cancer, breast cancer, stomach cancer and lung cancer Between 5 and 30 percent of these cancers carry the FGFR gene variant , two pan-FGFR inhibitors have been approved for sale worldwide One is the targeted drug erdafitinib, developed by Johnson and Johnson, which was approved in the United States in April 2019 to treat advanced bladder cancer with FGFR3 and FGFR2 mutations and gene fusion, and was approved for clinical practice in China in March this year The second is the targeted drug pemigatinib, developed by Incyte, which was approved in the United States in April this year to treat malignant bile duct cancer with the fused FGFR2 gene fusion In China, no FGFR inhibitors have been approved for the market, but many companies are already laying out this area, including Cinda Bio, Beida Pharmaceuticals, Lunsheng Pharmaceuticals and so on congratulates Nocheng Jianhua on the new clinical progress achieved in the study of The Pan FGFR inhibitor ICP-192, and wishes the follow-up research of the product progress smoothly and benefits more cancer patients at an early date .